Thermo Fisher Scientific OX40 (CD134) Recombinant Rabbit Monoclonal Antibody (RM313)

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000-1:2,000

-

Immunohistochemistry (Paraffin) (IHC (P))

1:200-1:500

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Expression System

HEK293 cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

RM313

Immunogen

A peptide corresponding to the C-terminus of human OX40 (CD134) if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:OX40 (CD134),uniProtId:P43489-1,ncbiNodeId:9606,antigenRange:277,antigenLength:277,antigenImageFileName:MA5-27895_OX40_CD134_P43489-1_Rabbit.svg,antigenImageFileNamePDP:MA5-27895_OX40_CD134_P43489-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Protein A

Storage buffer

PBS with 1% BSA, 50% glycerol

Contains

0.09% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2744949

Product Specific Information

Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

Target Information

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.